Csenge Advisory Group acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) in the second quarter, HoldingsChannel.com reports. The institutional investor acquired 6,326 shares of the life sciences company’s stock, valued at approximately $1,112,000.
A number of other hedge funds and other institutional investors have also bought and sold shares of ILMN. HighPoint Advisor Group LLC boosted its position in Illumina by 3.7% during the 4th quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock worth $291,000 after acquiring an additional 80 shares during the last quarter. Elevation Wealth Partners LLC grew its stake in shares of Illumina by 52.5% during the 2nd quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock worth $43,000 after acquiring an additional 84 shares in the last quarter. Meeder Advisory Services Inc. raised its holdings in shares of Illumina by 3.1% in the first quarter. Meeder Advisory Services Inc. now owns 2,822 shares of the life sciences company’s stock valued at $348,000 after purchasing an additional 85 shares during the last quarter. Toronto Dominion Bank raised its holdings in shares of Illumina by 0.3% in the fourth quarter. Toronto Dominion Bank now owns 33,605 shares of the life sciences company’s stock valued at $4,407,000 after purchasing an additional 92 shares during the last quarter. Finally, Panagora Asset Management Inc. lifted its position in shares of Illumina by 3.9% in the fourth quarter. Panagora Asset Management Inc. now owns 2,536 shares of the life sciences company’s stock worth $333,000 after purchasing an additional 96 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.
Illumina Trading Up 8.9%
NASDAQ ILMN opened at $205.00 on Thursday. Illumina, Inc. has a 12 month low of $88.00 and a 12 month high of $207.00. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. The stock has a 50 day moving average of $185.90 and a 200-day moving average of $151.49. The company has a market cap of $30.95 billion, a PE ratio of 38.25, a PEG ratio of 2.65 and a beta of 1.45.
Insider Activity
In other news, SVP Patricia Leckman sold 783 shares of the company’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $162.59, for a total value of $127,307.97. Following the sale, the senior vice president directly owned 21,259 shares of the company’s stock, valued at approximately $3,456,500.81. This represents a 3.55% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 457,858 shares of the company’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the completion of the sale, the director directly owned 2,372,694 shares in the company, valued at approximately $474,776,069.40. The trade was a 16.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 1,415,351 shares of company stock valued at $255,966,311 over the last quarter. 2.90% of the stock is currently owned by company insiders.
Analyst Upgrades and Downgrades
Several brokerages recently commented on ILMN. Deutsche Bank Aktiengesellschaft cut shares of Illumina to a “hold” rating in a report on Wednesday, August 5th. Canaccord Genuity Group boosted their price target on shares of Illumina from $190.00 to $205.00 and gave the stock a “hold” rating in a research report on Monday, August 3rd. Citigroup increased their price objective on shares of Illumina from $95.00 to $113.00 and gave the stock a “sell” rating in a research note on Monday, August 3rd. Guggenheim raised their price objective on Illumina from $200.00 to $226.00 and gave the company a “buy” rating in a report on Friday, July 31st. Finally, Barclays lifted their target price on Illumina from $145.00 to $160.00 and gave the company an “underweight” rating in a research report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $188.40.
View Our Latest Analysis on ILMN
Illumina Profile
Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.
The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.
Read More
- Five stocks we like better than Illumina
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN – Free Report).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
